Peter Tomasec

Date of Birth: 25-02-1970
Nationality: Slovak, British

Work address: Cardiff University School of Medicine, Institute of Infection and Immunity,

Henry Wellcome Building, Room GF-09, Heath Park, Cardiff CF14 4XN

EMPLOYMENT HISTORY

2002 - present:

Cardiff University School of Medicine, Institute of Infection and Immunity Lecturer in Molecular Virology and Immunology (tenured post funded by HEFCW, expected end date 2035)

1999 - 2002:

University of Wales College of Medicine, Section of Infection & Immunity, Cardiff Senior Research Fellow

1997 - 1999:

University of Wales College of Medicine, Department of Medicine, Cardiff Post-doctoral Scientist

EDUCATION

1994 - 1997:

University of Wales College of Cardiff and University of Manchester PhD student in Molecular Virology, PhD awarded in 1997

1992 - 1994:

University of Wales College of Cardiff
Post Graduate Research Course in Molecular Biology

1991 - 1992:

University of Dundee

Intercalated Research Course in Molecular Biology

1988 - 1992:

Slovak Technical University, Bratislava, Czechoslovakia BSc equivalent Chemistry/BiotechnologyNot clinically qualified Not clinically active

OTHER PROFESSIONAL ACTIVITIES

- Health&Safety Board, Cardiff University School of Medicine
- Scientific Advisory Board, Regional Centre for Applied Molecular Oncology, Brno

- External reviewer for Journal of General Virology, Journal of Virology, Journal of Immunology, Virology, Nature Immunology, PLoS Pathogens

RECENT SPEAKING ENGAGEMENTS

- 2015 UK CMV Workshop (Birmingham), invited keynote speaker
- 2015 Virtual Virology Seminar Series (University College London), invited speaker
- 2015 Wright Flemming Seminar Series (Imperial College London), invited speaker

PROFESSIONAL LINKS

- Paul Lehner (Cambridge University): development and application of proteomics and CRISPR technologies for study of virus biology
- Michael Weekes (Cambridge University): development and application of proteomics for study of virus biology
- Steve Gygi (Harward University): application of TMT proteomics technologies
- Andrew Davison (University of Glasgow): defining gene usage of human cytomegalovirus
- Borivoj Vojtesek (Regional Centre for Applied Molecular Oncology, Brno): immune recognition and immune therapies
- Chris Benedict (La Hola Institute for Allergy and Immunology): function of death receptors in immune recognition
- Dirk Zajonc (La Hola Institute for Allergy and Immunology): crystallography of viral immunomodulators, Tomasec is named collaborator on Zajonc's grants
- Ivana Nemcovicova (Institute of Virology, Bratislava): crystallography of viral immunomodulators, Tomasec is named collaborator on Zajonc's grants
- Veronika Groh (Fred Hutchinson Cancer Research Centre, Seattle): function of MICA/B antigens in immune recognition
- Veronique Braud (Nice University Sophia Antipolis): function of HLA-E in immune recognition
- Alexander Steinle (Goethe University Frankfurt am Main): function of MICA/B antigens in immune recognition
- Akio Nomoto (Institute of Microbial Chemistry, Tokyo): function of nectins in immune recognition
- Merck: development of immunoreagents and immune therapies
- NativeAntigen : development of immunodiagnostics

GRANTS AND FELLOWSHIPS

2015-2018: NISCHR PhD Fellowship (HS-14-11) to Stanton(lead), Wilkinson & Tomasec. The role of RL13 in human cytomegalovirus pathogenesis (£66K)

2014-2017: MRC Project Grant (MR/LO18373/1) awarded to Wilkinson(lead), Wang, Stanton and Tomasec. A systematic investigation into human cytomegalovirus gene function (£679K)

2010-2017: Wellcome Trust Programme Grant (GR04685/WT090323MA) awarded to Wilkinson(lead), Wang & Tomasec. Modulation of Host Immunity by Human Cytomegalovirus (£1.7M)

PERSONAL STATEMENT

I moved to UK in 1991 after winning a TEMPUS European Community competition to spend intercalated year at Dundee University. The placement allowed me to expand my training and horizons and included introduction to molecular biology. I became determined to continue my career in the UK as a molecular biologist and thus I secured personal fellowships (1992-1997) to further re-train. My PhD was productive and contributed to 9 original papers and two book chapters.

In 1997, Sir LK Borysiewicz and Prof GWG Wilkinson recruited me to the Department of Medicine in Cardiff and together we set out to build a virus immunology group focused on immune modulation by human cytomegalovirus (HCMV). We were fortunate and have made a major contribution towards understanding of viral immunomodulation and virus biology. Most notable, perhaps, have been our discoveries of 5 novel HCMV immunomodulatory functions, BAC cloning of HCMV wild type genome and establishing this BAC-cloned isolate as GenBank and WHO reference strain.

Currently, our group is focusing on developing and employment of cutting edge technologies of recombineering, mass spectrometry and -omics for further mapping and defining of HCMV functions associated with infection and immune system modulation. I am still research active and focussed on gene hunting, my other roles within our group include student and postdoc supervision and role of a group strategist.